EC approves Bristol-Myers Squibb’s opdivo (nivolumab) four-week dosing for RCC
Bristol-Myers Squibb announced the EC has approved an every four-week Opdivo (nivolumab) monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced melanoma and previously treated renal cell carcinoma. April 25, 2018